242 related articles for article (PubMed ID: 16075933)
1. An update on medical management of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Tanda ML; Piantanida E; Lai A; Marinò M; Pinchera A
J Endocrinol Invest; 2005 May; 28(5):469-78. PubMed ID: 16075933
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
3. [Graves' orbitopathy].
Balázs C
Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
[TBL] [Abstract][Full Text] [Related]
4. [Radiotherapy of Graves' ophthalmopathy--state of the art and review of the literature].
Eich HT; Micke O; Seegenschmiedt MH
Rontgenpraxis; 2007; 56(4):137-44. PubMed ID: 17390953
[TBL] [Abstract][Full Text] [Related]
5. Graves' ophthalmopathy: state of the art and perspectives.
Bartalena L; Wiersinga WM; Pinchera A
J Endocrinol Invest; 2004 Mar; 27(3):295-301. PubMed ID: 15165007
[TBL] [Abstract][Full Text] [Related]
6. Treating severe Graves' ophthalmopathy.
Bartalena L; Marcocci C; Pinchera A
Baillieres Clin Endocrinol Metab; 1997 Oct; 11(3):521-36. PubMed ID: 9532337
[TBL] [Abstract][Full Text] [Related]
7. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
Marcocci C; Marinò M
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
[TBL] [Abstract][Full Text] [Related]
8. Extrathyroidal manifestations of Graves' disease: a 2014 update.
Bartalena L; Fatourechi V
J Endocrinol Invest; 2014 Aug; 37(8):691-700. PubMed ID: 24913238
[TBL] [Abstract][Full Text] [Related]
9. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
[TBL] [Abstract][Full Text] [Related]
10. Management of Graves' ophthalmopathy: reality and perspectives.
Bartalena L; Pinchera A; Marcocci C
Endocr Rev; 2000 Apr; 21(2):168-99. PubMed ID: 10782363
[TBL] [Abstract][Full Text] [Related]
11. Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.
Marcocci C; Marinò M; Rocchi R; Menconi F; Morabito E; Pinchera A
J Endocrinol Invest; 2004 Mar; 27(3):272-80. PubMed ID: 15165004
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and prevention of Graves' ophthalmopathy.
Wiersinga WM; Bartalena L
Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
[TBL] [Abstract][Full Text] [Related]
13. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
14. Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous?
Bartalena L; Marcocci C; Gorman CA; Wiersinga WM; Pinchera A
J Endocrinol Invest; 2003 Jan; 26(1):5-16. PubMed ID: 12602528
[TBL] [Abstract][Full Text] [Related]
15. [Management of Graves' orbitopathy: evidence-based recommendations].
Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
[TBL] [Abstract][Full Text] [Related]
16. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
17. [Radiotherapy for Graves' ophthalmopathy].
Kuhnt T; Müller AC; Janich M; Gerlach R; Hädecke J; Duncker GI; Dunst J
Klin Monbl Augenheilkd; 2004 Nov; 221(11):915-21. PubMed ID: 15562354
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoids in the medical management of Graves' ophthalmopathy.
Hart RH; Perros P
Minerva Endocrinol; 2003 Sep; 28(3):223-31. PubMed ID: 14605604
[TBL] [Abstract][Full Text] [Related]
19. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.
Bartalena L; Baldeschi L; Boboridis K; Eckstein A; Kahaly GJ; Marcocci C; Perros P; Salvi M; Wiersinga WM;
Eur Thyroid J; 2016 Mar; 5(1):9-26. PubMed ID: 27099835
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
Brauer VF; Scholz GH
Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
